We are live on ! Find out more
ATOS icon

Atossa Therapeutics
ATOS

10 hedge funds and large institutions have $320K invested in Atossa Therapeutics in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.04% less ownership

Funds ownership: 0.22% → 0.18% (-0.04%)

29% less funds holding

Funds holding: 14 → 10 (-4)

32% less capital invested

Capital invested by funds: $471K → $320K (-$152K)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
10
Holders Change
-4
Holders Change %
-28.57%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$2.02K
2
FDCDDQ
Federation des caisses Desjardins du Quebec
Quebec, Canada
+$1.3K
3
Wells Fargo
Wells Fargo
California
+$79

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$41K
2
AIP
Ahrens Investment Partners
Louisiana
-$16K
3
Deutsche Bank
Deutsche Bank
Germany
-$10K
4
UBS Group
UBS Group
Switzerland
-$9K

ATOS Hedge Fund Activity: Q1 2020 in Review

10 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q1 2020, worth a combined $320K — down 32% from $471K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ATOS and 2 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Victory Capital Management, opening a new position worth an estimated $2.02K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $41K sold.

  • 10 institutional investors held Atossa Therapeutics (ATOS) as of Q1 2020, down from 14 in Q4 2019.
  • Funds reported $320K of Atossa Therapeutics stock for Q1 2020, down 32% quarter-over-quarter.
  • 2 funds opened new Atossa Therapeutics positions in Q1 2020 and 5 closed out, a net change of -3 holders.
  • The largest Atossa Therapeutics buyer in Q1 2020 was Victory Capital Management, an estimated $2.02K added.
  • The largest Atossa Therapeutics seller in Q1 2020 was Renaissance Technologies, an estimated $41K sold.

Based on aggregated 13F filings for Q1 2020.